KLK3 and prostate cancer: In the European Randomized Study of Screening for Prostate Cancer (ERSPC), after 9 years of follow-up in 162,387 men aged 55–69 years, PSA-based screening reduced PCa mortality by 20% but was associated with substantial overdiagnosis [4].